![Deborah Knobelman](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Deborah Knobelman
Directeur Financier/CFO chez
Senti Sub I, Inc.
Profil
Deborah A. Knobelman currently works at Senti Sub I, Inc., as Chief Financial Officer & Treasurer from 2021.
Dr. Knobelman also formerly worked at Kronos Bio, Inc., as President, Chief Executive Officer, COO, CFO & CAO from 2024 to 2025, Pfizer Inc., as Director-Commercial Strategy & Analytics from 2008 to 2011, Piper Sandler & Co. (Broker), as Senior Research Analyst, ThinkEquity Partners, as Senior Research Analyst, GC Royalty Holdings LLC, as Chief Financial Officer from 2016 to 2017, J.P.
Morgan & Co., Inc. (Old), as Research Associate, Senti Biosciences, Inc., as CFO, Treasurer & Head-Corporate Development from 2021 to 2024, and Ampio Pharmaceuticals, Inc., as Chief Business Officer from 2011 to 2012.
Dr. Knobelman received her undergraduate degree from Duke University and doctorate degree from the University of Pennsylvania Medical Center.
Postes actifs de Deborah Knobelman
| Sociétés | Poste | Début |
|---|---|---|
Senti Sub I, Inc.
 Senti Sub I, Inc. BiotechnologyHealth Technology Develops novel therapeutics | Directeur Financier/CFO | 01/05/2021 |
Anciens postes connus de Deborah Knobelman
| Sociétés | Poste | Fin |
|---|---|---|
| KRONOS BIO, INC. | Directeur Général | 20/06/2025 |
Senti Biosciences, Inc.
 Senti Biosciences, Inc. BiotechnologyHealth Technology Develops a synthetic biology platform that enables to program next-generation cell and gene therapies | Directeur Financier/CFO | 03/05/2024 |
GC Royalty Holdings LLC
 GC Royalty Holdings LLC Pharmaceuticals: GenericHealth Technology Develops and markets generic drugs | Directeur Financier/CFO | 01/07/2017 |
| AMPIO PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/04/2012 |
| PFIZER INC. | Corporate Officer/Principal | 01/08/2011 |
Formation de Deborah Knobelman
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
81
Relations au 1er degré
11
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 11 |
|---|---|
Pfizer Inc.
 Pfizer Inc. Pharmaceuticals: MajorHealth Technology Engages in discovery, development, manufacturing, marketing, sale and distribution of biopharmaceutical products & ingredients | Health Technology |
Piper Sandler & Co. (Broker)
 Piper Sandler & Co. (Broker) Investment Banks/BrokersFinance Provides brokerage services | Finance |
ThinkEquity Partners
 ThinkEquity Partners Investment ManagersFinance Provides investment advice and security brokerage services | Finance |
GC Royalty Holdings LLC
GC Royalty Holdings LLC Pharmaceuticals: GenericHealth Technology Develops and markets generic drugs | Health Technology |
Duke University
 Duke University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
J.P. Morgan & Co., Inc. (Old)
 J.P. Morgan & Co., Inc. (Old) Regional BanksFinance Provides commercial banking and investment advisory services | Finance |
Ampio Pharmaceuticals, Inc.
 Ampio Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops immuno modulatory therapies for the treatment of pain from osteoarthritis | Health Technology |
University of Pennsylvania Medical Center
 University of Pennsylvania Medical Center Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Senti Sub I, Inc.
Senti Sub I, Inc. BiotechnologyHealth Technology Develops novel therapeutics | Health Technology |
Kronos Bio, Inc.
 Kronos Bio, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops novel cancer therapeutics | Health Technology |
Senti Biosciences, Inc.
Senti Biosciences, Inc. BiotechnologyHealth Technology Develops a synthetic biology platform that enables to program next-generation cell and gene therapies | Health Technology |
